FANCA基因缺陷的恶性肿瘤患者使用PARP抑制剂的疗效研究

Study on the Efficacy of PARP Inhibitors in Patients with Malignant Tumors Defective in FANCA Gene

目的探讨PARP抑制剂对FANCA基因缺陷的恶性肿瘤患者的临床疗效。方法选择2020年2月—2021年2月在大庆龙南医院接受治疗的60例Ⅱ~Ⅲ期无乳腺癌易感基因(breast cancer susceptibility genes,BRCA)突变的卵巢癌患者为研究对象,根据FANCA基因检测结果将其分为有FANCA基因突变组(n=25)及无FANCA基因突变组(n=35),所有患者均接受完成4~6周期铂类基础方案化疗后再行PARP抑制剂维持治疗6个月,比较两组患者的客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)及不良反应发生情况。结果治疗6个月后,有FANCA基因突变组ORR、DCR分别为48.00%、84.00%,均明显高于无FANCA基因突变组的22.86%、57.14%,差异有统计学意义(χ^(2)=4.149、4.861,P<0.05)。两组患者均发生不同程度的不良反应,差异无统计学意义(P>0.05)。随访随访结果显示,有FANCA基因突变组患者PFS显著长于无FANCA基因突变组,差异有统计学意义(t=22.064,P<0.001)。结论FANCA突变的卵巢癌患者应用PARP抑制剂后的临床治疗效果显著,并可显著延长PFS。

Objective To investigate the clinical efficacy of PARP inhibitors in patients with malignant tumors defective in FANCA gene.Methods Sixty patients with stageⅡ-Ⅲovarian cancer without breast cancer susceptibility genes(BRAC)mutation treated in Daqing Longnan Hospital from February 2020 to February 2021 were selected for the study,who were divided into the group with FANCA gene mutation(n=25)and the group without FANCA gene mutation(n=35)according to the FANCA gene test results.All patients received the completion of 4-6 cycles of platinum-based regimen chemotherapy followed by PARP inhibitor maintenance therapy for 6 months.The objective remission rate(ORR)and disease control rate(DCR),progression-free survival(PFS)and the occurrence of adverse events were compared between the two groups.Results After 6 months of treatment,the ORR and DCR of patients in the group with FANCA gene mutation were 48.00%and 84.00%,respectively,which were significantly higher than those of patients in the group without FANCA gene mutation,which were 22.86%and 57.14%,and the difference was statistically significant(χ^(2)=4.149,4.861,P<0.05).The two groups of patients had adverse reactions of different degrees,but there was no statistically significant difference(P>0.05).Follow-up follow-up results showed that patients in the group with FANCA mutation had significantly longer PFS than those in the group without FANCA mutation,and the difference was statistically significant(t=22.064,P<0.001).Conclusion The clinical treatment effect of patients with ovarian cancer with FANCA mutation was significant after applying PARP inhibitors.and significantly prolonged PFS.